Warren Buffett Investing: Time to Buy These Struggling Stocks?

Warren Buffett is a proponent of value investing, but struggling stocks like Charlotte’s Web Holdings Inc. (TSX:CWEB) don’t necessarily fit this framework.

| More on:
TIMER SAYING TIME FOR ACTION

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Back in April, I’d discussed how Canadian investors could aim to emulate Warren Buffett in 2020. Buffett is a proponent of value investing. This is an investment strategy that involves choosing securities that appear to be trading for less than their intrinsic or book value. The strategy has faced challenges over the past decade. An era of loosening monetary policy has seen index investing blow up. However, value investing can still be extremely rewarding.

Warren Buffett investing: Do these weed stocks qualify?

The value investing strategy heralded by Warren Buffett requires that investors target stocks for high-quality companies. Today, I want to look at two cannabis stocks that have fallen to 52-week lows over the past week. Can these stocks fit the Buffett scenario in 2020? Let’s jump in and find out.

Charlotte’s Web Holdings (TSX:CWEB) produces and distributes hemp-based cannabidiol products in the United States. Its shares have dropped 59% in 2020 as of close on September 9. The company will release its second quarter 2020 results on September 14. In Q1 2020, Charlotte’s Web reported an adjusted EBITDA loss of $5.7 million.

Organic consolidated revenue came in at $21.5 million – down from $21.7 million in the prior year. Meanwhile, direct-to-consumer (DTC) e-commerce sales grew 29.4% over Q1 2019 and contributed 65% of total revenue. E-commerce markets have exploded due to the COVID-19 pandemic.

Charlotte’s Web stock last had an RSI of 34, putting just outside of technically oversold territory. The company has high growth potential in the U.S. However, the uncertainty in the CBD and hemp space south of the border makes it hard to qualify this stock under Warren Buffett’s value investing framework.

Can cannabis turn the corner to start this decade?

In early April, I’d discussed whether the cannabis sector was recession proof. Cannabis sales did spike in the early weeks of the pandemic. However, this proved to be unsustainable.

OrganiGram Holdings (TSX:OGI)(NASDAQ:OGI) produces and sells cannabis and cannabis-derived products in Canada. Its shares have plunged 49% over the past three months. The company released its third quarter 2020 results on July 21.

Net revenue fell to $18 million compared to $24 million in the prior year. Meanwhile, it generated positive cash flow from operations of $8.5 million. This was due to the monetization and optimization of working capital. Unfortunately, the company reduced its workforce by roughly 25% or 220 employees in June 2020 in response to conditions created by the COVID-19 pandemic.

OrganiGram is confident that it can make gains in the super-competitive Canadian cannabis market in the quarters to come. However, this is an industry that is suffering from oversupply and a rejuvenated black market. Once again, it is hard to envision Warren Buffett wanting to touch the cannabis sector.

Both Charlotte’s Web and OrganiGram have promising growth potential, but investors should know the risks before diving in. This is a gamble that does not fit with the spirit of value investing.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ambrose O'Callaghan has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Charlottes Web Holdings and OrganiGram Holdings. The Motley Fool recommends OrganiGram Holdings.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »